Published in J Virol on November 01, 2005
Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol (2009) 1.46
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther (2007) 1.19
Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther (2008) 1.17
Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol (2006) 1.14
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 1.13
Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J Virol (2006) 0.93
Mechanisms of neuroprotection from hypoxia-ischemia (HI) brain injury by up-regulation of cytoglobin (CYGB) in a neonatal rat model. J Biol Chem (2013) 0.91
Understanding and altering cell tropism of vesicular stomatitis virus. Virus Res (2013) 0.91
Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther (2011) 0.89
Gene therapy of liver cancer. World J Gastroenterol (2006) 0.86
Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol (2011) 0.82
Oncolytic virotherapy for advanced liver tumours. J Cell Mol Med (2008) 0.79
Advances in experimental and translational research in the treatment of hepatocellular carcinoma. Surg Oncol Clin N Am (2008) 0.78
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators Inflamm (2017) 0.75
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell (1996) 10.44
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
New mouse model for dengue virus vaccine testing. J Virol (1999) 3.18
The role of interferon in influenza virus tissue tropism. J Virol (1998) 2.88
Measles virus spread and pathogenesis in genetically modified mice. J Virol (1998) 2.84
Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med (2001) 2.64
Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol (2002) 2.44
Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J Virol (2000) 2.41
Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell (2000) 2.33
The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol (2001) 2.29
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10
Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell (2004) 1.93
The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol (2000) 1.89
The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter. J Virol (1997) 1.87
Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life (2000) 1.81
Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol (2001) 1.75
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 1.72
Impaired antiviral response in human hepatoma cells. Virology (1999) 1.52
Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res (2003) 1.50
Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol (2002) 1.49
Inhibition of vesicular stomatitis viral mRNA synthesis by interferons. J Virol (1987) 1.47
Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J Virol (1993) 1.39
The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus. Exp Cell Biol (1988) 1.36
Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res (2004) 1.23
Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther (2004) 1.21
Neuropathological and immunofluorescence studies of experimental vesicular stomatitis virus encephalitis in mice. J Neuropathol Exp Neurol (1971) 1.20
Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology (2005) 1.17
Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res (2004) 1.11
Interferon-induced gene expression and signaling in human hepatoma cell lines. J Hepatol (2000) 1.08
The isolation of interferon-inducing mutants of vesicular stomatitis virus with altered viral P function for the inhibition of total protein synthesis. Virology (1987) 1.06
Laboratory security and emergency response guidance for laboratories working with select agents. Centers for Disease Control and Prevention. MMWR Recomm Rep (2002) 1.04
Interferon induction as a quasispecies marker of vesicular stomatitis virus populations. J Virol (1998) 1.03
Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells. Virus Res (2001) 0.98
Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin Liver Dis (2004) 0.96
Immunohistochemical and behaviour pharmacological analysis of rats inoculated intranasally with vesicular stomatitis virus. J Chem Neuroanat (1993) 0.81
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev (2013) 2.96
HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest (2003) 2.89
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab (2003) 2.06
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90
Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes (2002) 1.87
Retracted A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst (2008) 1.84
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
Retracted The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene. Hum Gene Ther (2009) 1.70
Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl (2008) 1.68
Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. J Invest Dermatol (2009) 1.68
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci (2009) 1.61
Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol (2004) 1.58
Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res (2007) 1.53
Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery (2004) 1.51
Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol (2007) 1.51
Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res (2003) 1.50
Lymphoplasmacytic sclerosing pancreatitis: inflammatory mimic of pancreatic carcinoma. J Gastrointest Surg (2003) 1.49
Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46
De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44
Retracted Complete and persistent phenotypic correction of phenylketonuria in mice by site-specific genome integration of murine phenylalanine hydroxylase cDNA. Proc Natl Acad Sci U S A (2005) 1.43
Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther (2005) 1.43
Biologic predictors of survival in node-negative gastric cancer. Ann Surg (2003) 1.37
An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest (2002) 1.35
Retracted Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy. Mol Ther (2007) 1.25
Immunohistochemical evidence for hepatic progenitor cells in liver diseases. Liver (2002) 1.23
Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res (2004) 1.23
Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther (2004) 1.21
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther (2007) 1.19
Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology (2005) 1.17
A comprehensive, case-based review of groove pancreatitis. Pancreas (2009) 1.15
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 1.13
Retracted Site-specific transgene integration in the human genome catalyzed by phiBT1 phage integrase. Hum Gene Ther (2008) 1.13
Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol (2010) 1.11
Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol Ther (2003) 1.09
Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol (2011) 1.06
Morphologic features of extrahepatic manifestations of hepatitis C virus infection. Clin Dev Immunol (2012) 1.04
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun (2007) 1.03
A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation. Ann Surg (2007) 1.02
Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther (2007) 0.99
Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int (2005) 0.99
Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther (2009) 0.98
Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology (2008) 0.98
Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2005) 0.97
Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope (2007) 0.96
Hepatic cavernous hemangioma: underrecognized associated histologic features. Liver Int (2006) 0.95
Basal insulin gene expression significantly improves conventional insulin therapy in type 1 diabetic rats. Diabetes (2002) 0.95
Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther (2008) 0.94
Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol (2002) 0.93
Lymphocytic Esophagitis With CD4 T-cell-predominant Intraepithelial Lymphocytes and Primary Esophageal Motility Abnormalities: A Potential Novel Clinicopathologic Entity. Am J Surg Pathol (2015) 0.92
Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers. Liver (2002) 0.92
Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence. EMBO Mol Med (2013) 0.92
Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol Head Neck Surg (2007) 0.92
Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91
Destruction of canals of Hering in primary biliary cirrhosis. Hum Pathol (2002) 0.91
Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus. Int J Cancer (2005) 0.90
Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl (2009) 0.90
Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. J Hepatol (2011) 0.89
Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries. Jpn J Infect Dis (2003) 0.88
A versatile and tunable coating strategy allows control of nanocrystal delivery to cell types in the liver. Bioconjug Chem (2011) 0.88
Fulminant hepatic failure attributed to ackee fruit ingestion in a patient with sickle cell trait. Case Rep Transplant (2012) 0.87
Cholangiolocellular carcinoma in a pediatric patient with small duct sclerosing cholangitis: a case report. Semin Liver Dis (2013) 0.87
Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear β-catenin and glutamine synthetase positivity: case report and review of the literature. Am J Surg Pathol (2011) 0.87
Hepatocellular carcinoma associated with an atypical presentation of Wilson's disease. Semin Liver Dis (2007) 0.87
Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin Liver Dis (2009) 0.86
Hepatocellular carcinoma and congenital absence of the portal vein in a child receiving growth hormone therapy for turner syndrome. Semin Liver Dis (2007) 0.86
Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification. Int J Hepatol (2013) 0.86
Acute and chronic hepatitis. Semin Diagn Pathol (2007) 0.85
Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology (2012) 0.85
Preoperative radiological characterization of hepatic angiomyolipoma using magnetic resonance imaging and contrast-enhanced ultrasonography: a case report. J Med Case Rep (2011) 0.85
Invasive colloid carcinoma arising from intraductal papillary neoplasm in a 50-year-old woman with primary sclerosing cholangitis. Semin Liver Dis (2004) 0.84
Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth. J Orthop Res (2010) 0.84
Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope (2008) 0.84
Primary hepatic signet ring cell neuroendocrine tumor: a case report with literature review. Semin Liver Dis (2010) 0.84
Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol (2003) 0.84
gC1qR expression in normal and pathologic human tissues: differential expression in tissues of epithelial and mesenchymal origin. J Histochem Cytochem (2012) 0.84
Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis (2013) 0.83
A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer. J Immunother (2011) 0.82
Results of retransplantation for recurrent hepatitis C. Hepatology (2003) 0.82
Association of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinoma. World J Gastroenterol (2011) 0.82
Jaundice accompanied by giant cell hepatitis and eosinophilia in childhood. Semin Liver Dis (2004) 0.82